Analysis revealed alterations in immune-related pathways, including upregulation of the programmed cell death ligand 1 (PD-L1) and programmed death-1 (PD-1) cancer immunotherapy pathways and suppression of the Th1 pathway, indicating an imbalanced immune response in ARDS [19]. This evidence concerns the gene CD274 and cancer.